Key Highlights
- Tempus AI unveiled a broadened multi-year partnership with Gilead Sciences (GILD) designed to accelerate oncology drug development through its AI-powered Lens platform.
- Gilead now possesses enterprise-level access to Tempus’ anonymized multimodal datasets spanning numerous cancer types.
- Diagnostic revenues at Tempus surged 111.5% year-over-year in 2025, supported by a 26% increase in oncology testing volumes.
- The company’s Data and Applications division generated $100.4M in Q4 2025 revenue, marking 25.1% annual growth, while total contract value exceeded $1.1 billion.
- Over the past twelve months, TEM stock has climbed 17.9%, outperforming the medical information systems sector which declined 20%.
Tempus AI has announced a significant expansion of its existing collaboration with Gilead Sciences, strengthening a partnership that has been providing crucial real-world oncology insights for Gilead’s pharmaceutical research efforts.
Today we announced an expanded, multi-year collaboration with @GileadSciences aimed at building and advancing Gilead’s oncology pipeline.
“We are so excited to have entered into a strategic collaboration with Gilead whereby our multimodal data and AI-powered insights will… pic.twitter.com/W2cdJj1fnn
— Tempus (@TempusAI) April 9, 2026
Under the enhanced arrangement, Gilead gains comprehensive enterprise access to Tempus’ advanced AI-driven Lens analytics platform. This broadened access encompasses de-identified patient information across diverse cancer categories, complemented by specialized analytical support from Tempus’ expert team.
In earlier iterations of the partnership, Gilead leveraged Tempus’ data infrastructure for targeted applications—including clinical trial architecture, biomarker identification strategies, therapeutic indication selection, and health economics analysis. The current expansion significantly amplifies these capabilities.
Patrick Loerch, Senior Vice President of Clinical Data Science at Gilead, characterized the collaboration as exemplifying their “shared priority of putting patients at the heart of innovation.” Ryan Fukushima, CEO of Tempus Data & Apps, emphasized that the enhanced platform access would furnish AI-powered intelligence to bolster Gilead’s research and development initiatives. Neither company disclosed the financial arrangements.
Robust Diagnostic Performance Underpins Partnership Growth
This collaboration enhancement arrives alongside Tempus reporting particularly impressive diagnostic performance metrics.
Throughout 2025, Tempus‘ Diagnostics business unit achieved 111.5% revenue expansion compared to the prior year. Oncology test volumes increased 26%, Hereditary testing climbed 29%, and minimal residual disease (MRD) testing reached approximately 4,700 tests during Q4 alone—representing 56% sequential quarterly growth.
Company leadership anticipates roughly 30% oncology growth in 2026, propelled by increasing adoption of genomic sequencing technologies and broadening MRD reimbursement accessibility.
Additionally, the organization is navigating regulatory pricing enhancements, transitioning its xT CDx test from laboratory-developed status to FDA-approved designation. The average transaction price in Q4 2025 reached approximately $1,640, reflecting a $40 increase from the previous quarter.
Data Division Demonstrates Consistent Expansion
Tempus‘ Data and Applications business unit has emerged as a critical growth engine for the company.
Fourth quarter 2025 revenues for this segment totaled $100.4 million, representing 25.1% year-over-year growth. Net Revenue Retention measured 126%, signaling that current clients are increasing their platform investment. The company concluded 2025 with more than $1.1 billion in aggregate remaining contract obligations.
Leadership has issued guidance targeting approximately $1.59 billion in total 2026 revenues, suggesting roughly 25% annual growth.
Tempus continues investing in comprehensive AI foundation models trained on its exclusive datasets, with strategic plans to extend beyond oncology into radiology, cardiology, and neuropsychology applications.
The stock currently trades at a forward price-to-sales multiple of 5.02x, positioned below the sector median of 5.38x.
Meanwhile, Gilead has entered an aggressive acquisition cycle. The pharmaceutical giant has disclosed three transactions totaling approximately $15 billion, including a $7.8 billion purchase of Arcellx and a $5 billion agreement for Tubulis. Research analysts at TD Cowen, BMO Capital, and Truist Securities maintain Buy or Outperform recommendations on Gilead with target prices spanning $155 to $174.
